FY2026 · ended Apr 30, 2026 · Revenue $4,319, -0.7% YoY · Filed Jul 23, 2026
HeartSciences Inc. (HSCS) files with the SEC under industry code 6199, Finance Services. In fiscal 2026, which ended Apr 30, 2026, it reported revenue of $4,319 and a net loss of $9.1 million. Free cash flow was -$7.4 million. As of Jul 31, 2026 it held $29,906 in cash and investments and $281,570 in total debt.
Revenue
$4,319
-0.7% vs prior year
Net income
$-9.14M
-4.3% vs prior year
Operating cash flow
$-7.43M
-0.2% vs prior year
Free cash flow
$-7.43M
-0.2% vs prior year
EPS
$-9.34
+50.2% vs prior year
Dividend per share
$0.00
Shares outstanding
3.90M
+101.6% vs prior year
Net cash
$-251,664
as of Jul 31, 2026
Operating margin
-194787.4%
FY 2026
Company profile
- Industry
- Finance Services (SIC 6199)
- Listed as
- HSCS (Nasdaq), HSCSW (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- TX
- Headquarters
- Southlake, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1468492
- Former names
- Heart Test Laboratories, Inc. (until Oct 18, 2024)
Other Finance Services companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Apr 30, 2026 |
FY 2025 Apr 30, 2025 |
FY 2024 Apr 30, 2024 |
FY 2023 Apr 30, 2023 |
|---|---|---|---|---|
| Revenue | $4,319 | $4,350 | $18,600 | $5,150 |
| Operating income | -$8.4M | -$8.4M | -$6.3M | -$6.1M |
| Net income | -$9.1M | -$8.8M | -$6.6M | -$6.4M |
| Diluted EPS | — | -$9.34 | -$18.74 | -$80.00 |
| Operating cash flow | -$7.4M | -$7.4M | -$6.1M | -$5.8M |
| Free cash flow | -$7.4M | -$7.4M | -$6.1M | -$5.8M |
| Total assets | — | $4.2M | $9.5M | $3.3M |
| Total liabilities | — | $4.0M | $2.2M | $3.1M |
| Stockholders' equity | — | $205,171 | $7.3M | $230,557 |
| Cash and investments | — | $1.1M | $5.8M | $1.7M |
| Total debt | — | $434,045 | $536,338 | $565,870 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Oct 2, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 17, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 15, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Sep 14, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 20, 2026 | Aug 20, 2026 |
All 345 HeartSciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.